Novozymes A/S Reports Non-GAAP EPS of €0.78 and Revenue of €2.09 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Performance: Novozymes A/S reported a Non-GAAP EPS of €0.78 for the first half of the year.
Revenue Growth: The company achieved a revenue of €2.09 billion, reflecting a 14.2% increase year-over-year.
Industry Position: Novozymes is recognized as an industry leader with defensive characteristics and solid growth potential.
Additional Resources: The press release includes links to Seeking Alpha’s Quant Rating, historical earnings data, and a dividend scorecard for further financial insights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
